Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.
Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses new therapeutics and their role in gynecologic cancers.
Clinical Pearls
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More